Inactive Instrument

Other languages Cytori Therapeutics Inc Nasdaq

Equities

US23283K1051

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Plus Therapeutics, Inc. Announces Validation & Clinical Implementation of Csf-01 Leptomeningeal Cancer Cell Diagnostic	25/03
Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium Obisbemeda in Leptomeningeal Metastases	11/03
Plus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	06/03
Plus Therapeutics, Inc. Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting	20/11
Top Premarket Gainers	03/11
Plus Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter of 2023 and Calendar Year of 2024	01/23/01
Plus Therapeutics, Inc. announces an Equity Buyback for $0.5 million worth of its shares.	01/23/01
Plus Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	01/23/01
Plus Therapeutics, Inc. authorizes a Buyback Plan.	31/23/31
Plus Therapeutics, Inc. Completes Dosing in Cohort 4 of ReSPECT-LM Phase 1 Clinical Trial of Rhenium Obisbemeda in Leptomeningeal Metastases	10/23/10
Sector Update: Health Care Stocks Slipping Late Friday8 Afternoon	09/23/09
Sector Update: Health Care Stocks Slipping Friday Afternoon	08/23/08
Sector Update: Health Care	08/23/08
Biocept Signs Non-Exclusive Licensing Agreement With Plus Therapeutics on CNSide Tumor Cell Platform	08/23/08
Wall Street Set to Open Flat Friday as Investors Remain Wary of Potential Interest Rate Hike	08/23/08
Top Premarket Gainers	08/23/08
Plus Therapeutics, Inc. Initiates Part B of ReSPECT-LM Phase 1/2a Trial for Leptomeningeal Metastase	05/23/05
Plus Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15
Plus Therapeutics Says Leptomeningeal Metastases Phase 1 Trial of Rhenium Obisbemeda Showed Lower Tumor Cell Counts	11/23/11
Plus Therapeutics, Inc. Appoints Pius Maliakal as Vice President of Clinical Operations	28/23/28

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Cytori Therapeutics Inc Nasdaq

Equities

US23283K1051

Other languages

Filters